Oral GW766944 (Oral CCR3 Antagonist)

计划入组 60 人 · 首次发布于 2010 年 7 月 12 日

Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody

计划入组 15 人 · 首次发布于 2020 年 9 月 25 日

Vitamin K Antagonist Versus Direct Oral Anticoagulant Treatments in Hemophilia

计划入组 54 人 · 首次发布于 2023 年 4 月 7 日

C5aR1 Antagonists(Idorsia Pharmaceuticals)

C5AR1 inhibitors(Dompe Farmaceutici)

Complement Receptor C5aR1(Vanqua Bio)

Oral-B Laboratories

United States

Philips Oral Healthcare

United States

ORAL RECONSTRUCTION FOUNDATION

United States

Biogen Acquires Exclusive Rights to Vanqua Bio's C5aR1 Antagonist for Inflammatory Diseases in $1.06 Billion Deal

Oral CCR4 Antagonist RPT193 Shows Promise in Atopic Dermatitis Phase 1 Trial

Evommune's Oral MRGPRX2 Antagonist EVO756 Fails Phase 2b in Atopic Dermatitis, Program Halted